Compare ULY & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ULY | DRMA |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 4.2M |
| IPO Year | 2023 | N/A |
| Metric | ULY | DRMA |
|---|---|---|
| Price | $2.05 | $1.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $11.50 | $10.00 |
| AVG Volume (30 Days) | 25.6K | ★ 2.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $142,905,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $0.59 |
| 52 Week High | $17.99 | $7.33 |
| Indicator | ULY | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 44.44 |
| Support Level | $1.81 | $0.63 |
| Resistance Level | $2.74 | $2.29 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 62.53 | 18.60 |
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology for patients suffering with acne. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin.